Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department can take to accelerate the approval of the drug Sacituzumab Govitecan, marketed as Trodelvy, by the Medicine and Healthcare products Regulatory Authority.

The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of the importance of Trodelvy and is participating in several new schemes designed to speed up its availability.

Earlier this year, a licence application for Trodelvy in metastatic triple negative breast cancer was filed in the United Kingdom as part of Project Orbis. The United States approval is being considered and the MHRA is currently evaluating the application for Trodelvy.